Atorvastatin
Based on 66 publication(s) in Google Scholar
Atorvastatin is an orally active HMG-CoA reductase inhibitor, has the ability to effectively decrease blood lipids. Atorvastatin inhibits human SV-SMC proliferation and invasion with IC50s of 0.39 μM and 2.39 μM, respectively.
For research use only. We do not sell to patients.
- Purity: 99.60%
- CAS No.: 134523-00-5
- Formula: C33H35FN2O5
- Molecular Weight:558.64
-
Storage:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
Publications Citing Use of MedChemExpress (MCE) Atorvastatin
More- Signal Transduct Target Ther. 2025 Nov 12;10(1):366. [Abstract]
- Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]
- Nat Metab. 2025 Oct;7(10):2142-2164. [Abstract]
- Nat Aging. 2025 Aug 26. [Abstract]
- Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. [Abstract]
- Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]
- MedComm (2020). 2024 Aug 31;5(9):e681. [Abstract]
- Cancer Lett. 2023 Jan 1:552:215976. [Abstract]
- Cell Death Dis. 2021 May 13;12(5):482. [Abstract]
- Cell Commun Signal. 2026 Mar 23;24(1):259. [Abstract]
- Environ Sci Technol Lett. 2025 Apr 8.
- Acta Pharmacol Sin. 2024 Jun;45(6):1316-1320. [Abstract]
- Phytomedicine. 2025 Oct:146:157128. [Abstract]
- Phytomedicine. 2025 Jul:142:156713. [Abstract]
- Phytomedicine. 2023 Jul 26;119:154997. [Abstract]
- Free Radic Biol Med. 2024 Aug 1:220:179-191. [Abstract]
- Emerg Microbes Infect. 2025 Dec;14(1):2470371. [Abstract]
- Biomed Pharmacother. 2023 Oct:166:115323. [Abstract]
- Arterioscler Thromb Vasc Biol. 2022 May;42(5):644-658. [Abstract]
- Oncogene. 2022 Dec;41(49):5266-5278. [Abstract]
- Eur J Med Chem. 2024 Dec 5:279:116842. [Abstract]
- Clin Pharmacol Ther. 2025 Jul 14. [Abstract]
- Pharmaceutics. 2022 Jan 12;14(1):176. [Abstract]
- Chem Biol Interact. 2025 Oct 22:420:111671. [Abstract]
- Life Sci. 2025 Jun 1:370:123571. [Abstract]
- Inflammation. 2024 Oct 31. [Abstract]
- Int J Mol Sci. 2023 Apr 19;24(8):7492. [Abstract]
- Ann N Y Acad Sci. 2026 Mar;1557(1):e70224. [Abstract]
- Front Pharmacol. 2025 Apr 30:16:1573032. [Abstract]
- Front Bioeng Biotechnol. 2022 Mar 17;10:826093. [Abstract]
- Int Immunopharmacol. 2026 Apr 1:174:116259. [Abstract]
- Int Immunopharmacol. 2026 Apr 1:174:116346. [Abstract]
- Int Immunopharmacol. 2025 Dec 3:166:115644. [Abstract]
- Eur J Pharmacol. 2025 Feb 5:177357. [Abstract]
- Eur J Pharmacol. 2024 Feb 5:964:176261. [Abstract]
- Eur J Pharmacol. 2023 Oct 5:956:175938. [Abstract]
- Nanomedicine. 2026 Mar;21(6):789-801. [Abstract]
- Front Cell Dev Biol. 2022 Mar 3;10:806081. [Abstract]
- Exp Neurol. 2025 May 16:115305. [Abstract]
- Proteomics. 2023 Aug;23(16):e2300041. [Abstract]
- Sci Rep. 2020 Jan 28;10(1):1308. [Abstract]
- J Nat Prod. 2022 Jul 22;85(7):1738-1750. [Abstract]
- Biotechnol Bioeng. 2021 Dec;118(12):4687-4698. [Abstract]
- Exp Cell Res. 2023 Dec 15;433(2):113829. [Abstract]
- Cell Cycle. 2021 Oct;20(20):2160-2173. [Abstract]
- Cell Cycle. 2019 Dec;18(23):3337-3350. [Abstract]
- Endocrinology. 2022 Jul 1;163(7):bqac076. [Abstract]
- Endocrinology. 2018 May 1;159(5):2008-2021. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2023 Dec;396(12):3659-3670. [Abstract]
- Arch Biochem Biophys. 2025 Jan 21:765:110316. [Abstract]
- J Tradit Complement Med. 2024 Mar 29;14(6):656-665. [Abstract]
- Acta Diabetol. 2025 Mar 27. [Abstract]
- Med Gas Res. 2025 Mar 1;15(1):148-155. [Abstract]
- J Appl Toxicol. 2024 Aug;44(8):1198-1213. [Abstract]
- J Mol Neurosci. 2022 Mar;72(3):565-573. [Abstract]
- Oncologie. 2025 May 26.
- J Neuroimmunol. 2020 Oct 24:350:577429. [Abstract]
- FEBS Open Bio. 2025 Aug 8. [Abstract]
- SSRN. 2026 May 20.
- Res Sq. 2026 Jan 9.
- SSRN. 2025 Apr 9.
- Orebro University. 2024.
- bioRxiv. 2024 Jul 3:2024.07.01.601474. [Abstract]
- Research Square Preprint. 2024 Apr 9.
- Research Square Preprint. 2022 Jun.
- Research Square Preprint. 2021 Dec.
-
Flow Cytometry
-
ELISA
-
WB
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
Biological Activity
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| A549 | IC50 |
8.7 μM
Compound: atorvastatin
|
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
Cytotoxicity against human A549 cells after 72 hrs by MTT assay
|
[PMID: 23570542] |
| HEK293 | IC50 |
0.6 μM
Compound: Atorvastatin
|
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estradiol-17beta-glucuronide substrate
|
[PMID: 22587986] |
| HEK293 | IC50 |
0.8 μM
Compound: Atorvastatin
|
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using pitavastatin substrate
|
[PMID: 22587986] |
| HEK293 | IC50 |
1.6 μM
Compound: Atorvastatin
|
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate
Inhibition of OATP1B1 (unknown origin) expressed in HEK293 cells using estrone-3-sulfate substrate
|
[PMID: 22587986] |
| Hepatocyte | IC50 |
0.99 nM
Compound: atorvastatin
|
Inhibition of cholesterol synthesis in rat hepatocyte
Inhibition of cholesterol synthesis in rat hepatocyte
|
[PMID: 18155906] |
| Hepatocyte | IC50 |
2.5 nM
Compound: atorvastatin
|
Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol
Inhibition of cholesterol synthesis in rat hepatocytes assessed as incorporation of [14C]acetate into cholesterol
|
[PMID: 18412317] |
| Hs68 | IC50 |
22.7 μM
Compound: atorvastatin
|
Cytotoxicity against human HS68 cells after 72 hrs by MTT assay
Cytotoxicity against human HS68 cells after 72 hrs by MTT assay
|
[PMID: 23570542] |
| L6 | IC50 |
142 nM
Compound: atorvastatin
|
Inhibition of cholesterol synthesis in rat L6 myocyte
Inhibition of cholesterol synthesis in rat L6 myocyte
|
[PMID: 18155906] |
| L6 | IC50 |
78 nM
Compound: atorvastatin
|
Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol
Inhibition of cholesterol synthesis in rat L6 cells assessed as incorporation of [14C]acetate into cholesterol
|
[PMID: 18412317] |
| MEF | IC50 |
30.7 μM
Compound: atorvastatin
|
Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay
Cytotoxicity against mouse MEF cells after 72 hrs by MTT assay
|
[PMID: 23570542] |
Atorvastatin treatment decreases apoptosis of myocardial cells by down-regulating GRP78, caspase-12 and CHOP expression in myocardial cells after myocardial infarction, and the endoplasmic reticulum (ER) stress is activated in response to heart failure and angiotensin II (Ang II) stimulation[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Forty 8-week-old ApoE−/− mice induced with angiotensin II (Ang II)[5]
-
Dosage:20 mg/kg, 30 mg/kg
-
Administration:Oral gavage; once a day; for 28 days
-
Result:Significantly reduced ER stress signaling proteins, the number of apoptotic cells, and the activation of Caspase12 and Bax in the Ang II-induced ApoE−/− mice. Proinflammatory cytokines such as IL-6, IL-8, IL-1β were all remarkably inhibited.
Chemical Information
-
CAS No. 134523-00-5
-
Appearance Solid
-
Molecular Weight 558.64
-
Formula C33H35FN2O5
-
Color White to light yellow
-
SMILES
O=C(C(C(C1=CC=CC=C1)=C(C2=CC=C(F)C=C2)N3CC[C@@H](O)C[C@@H](O)CC(O)=O)=C3C(C)C)NC4=CC=CC=C4
-
Shipping
Room temperature in continental US; may vary elsewhere.
-
Storage
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (66)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
2025 Nov 12;10(1):366. PMID: 41219186 -
Signal Transduct Target Ther
2023 Dec 25;8(1):457. PMID: 38143263
Atorvastatin purchased from MedChemExpress. Usage Cited in: Signal Transduct Target Ther. 2023 Dec 25;8(1):457. [Abstract]
EGFRvIII-high U87 cells were cocultured with EGFRvIII-CAR-T cells and treated with Atorvastatin (5 μM, 3 days) or Cytochalasin D (10 μg/mL, 1 day). Immunoblotting of magnetically separated cells showed that both drugs alleviated CAR molecule transfer (representative of three independent experiments).
-
Nat Metab
2025 Oct;7(10):2142-2164. PMID: 40983680
Atorvastatin purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Oct;7(10):2142-2164. [Abstract]
Representative histogram and quantification of normalized MHC I membrane levels determined by flow cytometry (stained for anti-HLA-A, anti-HLA-B and anti-HLA-C) in response to indicated treatment conditions in iAstrocytes (N = 4–6; three (control and cholesterol) or two (Atorvastatin hemicalcium salt) independent experiments from two isogenic sets. Data are shown as the mean. *P < 0.05 (two-sided one-sample t-test for cholesterol and atorvastatin versus 1).
Atorvastatin purchased from MedChemExpress. Usage Cited in: Nat Metab. 2025 Oct;7(10):2142-2164. [Abstract]
Secreted Il-6 levels in medium of ApoE3 iAstrocytes that were pretreated with or without exogenous Cholesterol (10 μM) or Atorvastatin hemicalcium salt (0.5 μM) for 1 h before 24-h cotreatment with increasing doses of TNF, IL-1α and C1q.
-
Nat Aging
2025 Aug 26. PMID: 40858817 -
Mol Cell
The ZMYND8-regulated mevalonate pathway endows YAP-high intestinal cancer with metabolic vulnerability. [Abstract]2021 Jul 1;81(13):2736-2751.e8. PMID: 33932349
Atorvastatin purchased from MedChemExpress. Usage Cited in: Mol Cell. 2021 Jul 1;81(13):2736-2751.e8. [Abstract]
Tumor volumes of indicated patient-derived xenografts (PDXs) treated with Atorvastatin (40 mg/kg, i.p., every two days for 30 days).
-
Adv Sci (Weinh)
Short-Term Statin Therapy Induces Hepatic Insulin Resistance Through HNF4α/PAQR9/PPM1α Axis Regulated AKT Phosphorylation. [Abstract]2024 Jul 5:e2403451. PMID: 38970167
Atorvastatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]
Representative images of p-AKT1 staining of liver sections of the DMSO, Simvastatin and Atorvastatin hemicalcium salt (20 mg/kg, 3 days, atorvastatin with HFD)‐treated mice.
Atorvastatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]
Western blotting of PAQR9 in mouse primary hepatocytes under the treatment of DMSO, Simvastatin (Sim), Atorvastatin hemicalcium salt (Ator, 10 mmol/L, 24-48 h) and Rosuvastatin (Rosu).
Atorvastatin purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 5:e2403451. [Abstract]
The top 20 predicted transcription factors of differentially expressed genes under Atorvastatin hemicalcium salt treatment. The gene expression data were from GEO datasets GSE24188 and the TF prediction was by ChEA3. The bar showed rank score and the line showed the number of overlapped genes.
-
MedComm (2020)
Statins, but not proprotein convertase subtilisin-kexin type 9 inhibitors, lower chemerin in hypercholesterolemia via low-density lipoprotein receptor upregulation. [Abstract]2024 Aug 31;5(9):e681. PMID: 39220103 -
Cancer Lett
Mutant p53 driven-LINC00857, a protein scaffold between FOXM1 and deubiquitinase OTUB1, promotes the metastasis of pancreatic cancer. [Abstract]2023 Jan 1:552:215976. PMID: 36272615
Atorvastatin purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2023 Jan 1:552:215976. [Abstract]
Panc-1 and MIA PaCa-2 cells were treated with Atorvastatin (20 μM or 50 μM) for 24 h. FOXM1 and mutant p53 protein levels were measured in different treatment groups.
-
Cell Death Dis
Targeting epigenetic modulation of cholesterol synthesis as a therapeutic strategy for head and neck squamous cell carcinoma. [Abstract]2021 May 13;12(5):482. PMID: 33986254 -
Cell Commun Signal
Atorvastatin promotes lipid catabolism in colorectal cancer via FDFT1‒mediated inhibition of the PI3K/AKT pathway. [Abstract]2026 Mar 23;24(1):259. PMID: 41866501 -
Atorvastatin purchased from MedChemExpress. Usage Cited in: Environ Sci Technol Lett. 2025 Apr 8.
The hCMEC-D3 cells were exposed to 0.01 μM 77PD-Q for 24 h in the presence or absence of 0.3 μM Atorvastatin (0.3 μM, 24 h).
-
Acta Pharmacol Sin
2024 Jun;45(6):1316-1320. PMID: 38459255 -
Phytomedicine
Mori fructus-derived extracellular vesicle-like nanoparticles regulate dyslipidemia and prevent atherosclerosis progression via miRNAs. [Abstract]2025 Oct:146:157128. PMID: 40815949
Atorvastatin purchased from MedChemExpress. Usage Cited in: Phytomedicine. 2025 Oct:146:157128. [Abstract]
ApoE-/- mice were administrated with high-fat-diet accompanied by MFEVLPs (5 or 50 μg/d, i.p) or Atorvastatin (10 mg/kg/day, i.g) for 12 weeks.
-
Phytomedicine
Bioactive equivalent combinatorial components of Xiao-Xu-Ming decoction inhibit the calmodulin-mediated MLCK/MLC axis to attenuate coronary artery spasm. [Abstract]2025 Jul:142:156713. PMID: 40349422 -
Phytomedicine
Dihydromyricetin confers cerebroprotection against subarachnoid hemorrhage via the Nrf2-dependent Prx2 signaling cascade. [Abstract]2023 Jul 26;119:154997. PMID: 37523836 -
Free Radic Biol Med
Atorvastatin combined with imipenem alleviates lung injury in sepsis by inhibiting neutrophil extracellular trap formation via the ERK/NOX2 signaling pathway. [Abstract]2024 Aug 1:220:179-191. PMID: 38704053 -
Emerg Microbes Infect
SREBP2-dependent lipid droplet formation enhances viral replication and deteriorates lung injury in mice following IAV infection. [Abstract]2025 Dec;14(1):2470371. PMID: 39968754 -
Biomed Pharmacother
2023 Oct:166:115323. PMID: 37579692 -
Arterioscler Thromb Vasc Biol
N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells. [Abstract]2022 May;42(5):644-658. PMID: 35296150 -
Oncogene
Targeting the cholesterol-RORα/γ axis inhibits colorectal cancer progression through degrading c-myc. [Abstract]2022 Dec;41(49):5266-5278. PMID: 36316442
Atorvastatin purchased from MedChemExpress. Usage Cited in: Oncogene. 2022 Dec;41(49):5266-5278. [Abstract]
ATP assay. The combination of Atorvastatin (2.5, 5, 10, 20 μM; 48 h) and SR1078 synergistically inhibits CRC cell viability.
-
Eur J Med Chem
2024 Dec 5:279:116842. PMID: 39260319 -
Clin Pharmacol Ther
Advancing Predictions of Oral Drug Absorption, CYP3A4 Induction, and Transporter-Mediated Interactions Using a Human Primary Intestinal 3D Model (EpiIntestinal™). [Abstract]2025 Jul 14. PMID: 40657937 -
Pharmaceutics
Drug Repurposing for the Identification of Compounds with Anti-SARS-CoV-2 Capability via Multiple Targets. [Abstract]2022 Jan 12;14(1):176. PMID: 35057070 -
Chem Biol Interact
Subchronic exposure to CeCl3 promotes macrophage ferroptosis and atherosclerotic plaque formation by inhibiting the Keap1/Nrf2/GPX4 pathway. [Abstract]2025 Oct 22:420:111671. PMID: 40706741 -
Life Sci
CKN reduces TLR4-mediated inflammation and cerebral I/R injury by activating the LXRα/ABCA1 pathway in microglia. [Abstract]2025 Jun 1:370:123571. PMID: 40107493 -
Inflammation
2024 Oct 31. PMID: 39480573 -
Int J Mol Sci
Effects of Dietary Cholesterol Regulation on Spermatogenesis of Gobiocypris rarus Rare Minnow. [Abstract]2023 Apr 19;24(8):7492. PMID: 37108655 -
Ann N Y Acad Sci
The TRIB1-PPARγ Axis Regulates Cholesterol Metabolism in Pancreatic Ductal Adenocarcinoma. [Abstract]2026 Mar;1557(1):e70224. PMID: 41774091 -
Front Pharmacol
Canagliflozin alleviates progestin resistance by suppressing RARβ/CRABP2 signaling in THRB knockout endometrial cancer cells. [Abstract]2025 Apr 30:16:1573032. PMID: 40371351 -
Front Bioeng Biotechnol
Application of 3D Hepatic Plate-Like Liver Model for Statin-Induced Hepatotoxicity Evaluation. [Abstract]2022 Mar 17;10:826093. PMID: 35372314 -
Int Immunopharmacol
High-cholesterol-load-triggered pyroptosis of gingival fibroblasts promotes periodontitis. [Abstract]2026 Apr 1:174:116259. PMID: 41707588 -
Int Immunopharmacol
Milk exosomes loaded with atorvastatin suppress fibroblast activation and extracellular matrix remodeling via the TGF-β/SMAD pathway in ligamentum flavum hypertrophy. [Abstract]2026 Apr 1:174:116346. PMID: 41707594 -
Int Immunopharmacol
Structural polysaccharide PCP1 from Polygonatum cyrtonema Hua attenuates atherosclerosis via dual-target suppression of CD36/MSR1 and TLR4/NF-κB pathways. [Abstract]2025 Dec 3:166:115644. PMID: 41045802 -
Eur J Pharmacol
Protective effects of atorvastatin on testicular dysfunction and reduced sperm quality induced by high-fat diet in mice: The inhibitory mechanism of oxidative stress. [Abstract]2025 Feb 5:177357. PMID: 39921059 -
Eur J Pharmacol
Atorvastatin exerts dual effects of lesion regression and ovarian protection in the prevention and treatment of endometriosis. [Abstract]2024 Feb 5:964:176261. PMID: 38141938 -
Eur J Pharmacol
DL-3-n-butylphthalide improves the endothelium-dependent vasodilation in high-fat diet-fed ApoE-/- mice via suppressing inflammation, endothelial necroptosis and apoptosis. [Abstract]2023 Oct 5:956:175938. PMID: 37536623 -
Nanomedicine
Precise atorvastatin delivery by cardiac homing peptide functionalized nanoliposomes for myocardial damage repair after myocardial infarction. [Abstract]2026 Mar;21(6):789-801. PMID: 41660754 -
Front Cell Dev Biol
Atorvastatin Induces Mitochondria-Dependent Ferroptosis via the Modulation of Nrf2-xCT/GPx4 Axis. [Abstract]2022 Mar 3;10:806081. PMID: 35309902 -
Exp Neurol
Salvianolic acid B exerts cerebroprotective effects after traumatic brain injury via Nrf2-dependent antioxidant and anti-inflammatory cascades. [Abstract]2025 May 16:115305. PMID: 40383364 -
Proteomics
A proteomic signature and potential pharmacological opportunities in the adaptive resistance to MEK and PI3K kinase inhibition in pancreatic cancer cells. [Abstract]2023 Aug;23(16):e2300041. PMID: 37140101 -
Sci Rep
Scutellarin inhibition of the rosuvastatin uptake in rat hepatocytes and the competition for organic anion transporting polypeptide 1B1 in HEK293T cells. [Abstract]2020 Jan 28;10(1):1308. PMID: 31992796 -
J Nat Prod
Xyloketal B Reverses Nutritional Hepatic Steatosis, Steatohepatitis, and Liver Fibrosis through Activation of the PPARα/PGC1α Signaling Pathway. [Abstract]2022 Jul 22;85(7):1738-1750. PMID: 35749236 -
Biotechnol Bioeng
An integrated biomimetic array chip for establishment of collagen-based 3D primary human hepatocyte model for prediction of clinical drug-induced liver injury. [Abstract]2021 Dec;118(12):4687-4698. PMID: 34478150 -
Exp Cell Res
Rapamycin promotes hematoma resorption and enhances endothelial cell function by suppressing the mTOR/STAT3 signaling in chronic subdural hematoma. [Abstract]2023 Dec 15;433(2):113829. PMID: 37879548 -
Cell Cycle
Atorvastatin inhibited TNF-α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-κB signaling. [Abstract]2021 Oct;20(20):2160-2173. PMID: 34494933 -
Cell Cycle
Cholesterol depletion sensitizes gallbladder cancer to cisplatin by impairing DNA damage response. [Abstract]2019 Dec;18(23):3337-3350. PMID: 31599189 -
Endocrinology
2022 Jul 1;163(7):bqac076. PMID: 35583599 -
Endocrinology
miR-1224-5p Enhances Hepatic Lipogenesis by Targeting Adenosine Monophosphate-Activated Protein Kinase α1 in Male Mice. [Abstract]2018 May 1;159(5):2008-2021. PMID: 29474539
Atorvastatin purchased from MedChemExpress. Usage Cited in: Endocrinology. 2018 May 1;159(5):2008-2021. [Abstract]
Male C57BL/6 mice are intragastrically treated with Atorvastatin (0.1 mg/kg/day) and placebo for 10 weeks in the presence of HFD after 10-week-HFD feeding and then sacrificed for sample collection. H&E and oil red O staining of frozen liver sections.
-
Naunyn Schmiedebergs Arch Pharmacol
Bisdemethoxycurcumin suppresses the progression of atherosclerosis and VSMC-derived foam cell formation by promoting lipophagy. [Abstract]2023 Dec;396(12):3659-3670. PMID: 37289282 -
Arch Biochem Biophys
Astaxanthin-loaded polylactic acid-glycolic acid nanoparticles alleviates atherosclerosis by suppressing macrophage ferroptosis via the NRF2/SLC7A11/GPX4 pathway. [Abstract]2025 Jan 21:765:110316. PMID: 39848420 -
J Tradit Complement Med
Zhilong Huoxue Tongyu capsule protects against atherosclerosis by suppressing EndMT via modulating Hippo/YAP signaling pathway. [Abstract]2024 Mar 29;14(6):656-665. PMID: 39850597 -
Acta Diabetol
Identification of FLVCR1 as the iron metabolism-related gene of statin-associated diabetes. [Abstract]2025 Mar 27. PMID: 40146399 -
Med Gas Res
The augment effects of magnesium hydride on the lipid lowering effect of atorvastatin: an in vivo and in vitro investigation. [Abstract]2025 Mar 1;15(1):148-155. PMID: 39436189 -
J Appl Toxicol
2024 Aug;44(8):1198-1213. PMID: 38639436 -
J Mol Neurosci
Atorvastatin-Induced Absorption of Chronic Subdural Hematoma Is Partially Attributed to the Polarization of Macrophages. [Abstract]2022 Mar;72(3):565-573. PMID: 34569007 -
-
J Neuroimmunol
The combined treatment of NAD+ and atorvastatin ameliorates the development of experimental autoimmune encephalomyelitis in C57BL/6 mice. [Abstract]2020 Oct 24:350:577429. PMID: 33176238 -
FEBS Open Bio
Statins induce monocytic differentiation in acute myeloid leukemia cells through the KLF4/DPYSL2A axis. [Abstract]2025 Aug 8. PMID: 40781787 -
-
-
-
-
bioRxiv
The Neurolipid Atlas: a lipidomics resource for neurodegenerative diseases uncovers cholesterol as a regulator of astrocyte reactivity impaired by ApoE4. [Abstract]2024 Jul 3:2024.07.01.601474. PMID: 39005258 -
-
-
Solvent & Solubility
DMSO : ≥ 100 mg/mL (179.01 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.48 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 0.5% CMC/saline water
Solubility: 7.52 mg/mL (13.46 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation
-
Data Sheet (284 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
References
[1]. Santodomingo-Garzón T, et al. Atorvastatin inhibits inflammatory hypernociception. Br J Pharmacol. 2006 Sep;149(1):14-22. [Content Brief]
[2]. Turner NA, et al. Comparison of the efficacies of five different statins on inhibition of human saphenous vein smooth muscle cell proliferation and invasion. J Cardiovasc Pharmacol. 2007 Oct;50(4):458-61. [Content Brief]
[3]. Nawrocki, J.W., et al., Reduction of LDL cholesterol by 25% to 60% in patients with primary hypercholesterolemia by atorvastatin, a new HMG-CoA reductase inhibitor. Arterioscler Thromb Vasc Biol, 1995. 15(5): p. 678-82. [Content Brief]
[4]. Song XJ, et al. Atorvastatin inhibits myocardial cell apoptosis in a rat model with post-myocardial infarction heart failure by downregulating ER stress response. Int J Med Sci. 2011;8(7):564-72. [Content Brief]
[5]. Li Y, et al. Inhibition of endoplasmic reticulum stress signaling pathway: A new mechanism of statins to suppress the development of abdominal aortic aneurysm. PLoS One. 2017 Apr 3;12(4):e0174821. [Content Brief]
[6]. Ming-Bai Hu, et al. Atorvastatin induces autophagy in MDA-MB-231 breast cancer cells. Ultrastruct Pathol. Sep-Oct 2018;42(5):409-415. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 1.7901 mL | 8.9503 mL | 17.9006 mL | 44.7515 mL |
| 5 mM | 0.3580 mL | 1.7901 mL | 3.5801 mL | 8.9503 mL | |
| 10 mM | 0.1790 mL | 0.8950 mL | 1.7901 mL | 4.4752 mL | |
| 15 mM | 0.1193 mL | 0.5967 mL | 1.1934 mL | 2.9834 mL | |
| 20 mM | 0.0895 mL | 0.4475 mL | 0.8950 mL | 2.2376 mL | |
| 25 mM | 0.0716 mL | 0.3580 mL | 0.7160 mL | 1.7901 mL | |
| 30 mM | 0.0597 mL | 0.2983 mL | 0.5967 mL | 1.4917 mL | |
| 40 mM | 0.0448 mL | 0.2238 mL | 0.4475 mL | 1.1188 mL | |
| 50 mM | 0.0358 mL | 0.1790 mL | 0.3580 mL | 0.8950 mL | |
| 60 mM | 0.0298 mL | 0.1492 mL | 0.2983 mL | 0.7459 mL | |
| 80 mM | 0.0224 mL | 0.1119 mL | 0.2238 mL | 0.5594 mL | |
| 100 mM | 0.0179 mL | 0.0895 mL | 0.1790 mL | 0.4475 mL |